Emerging protein-based immunotherapies could lead to highly effective cancer treatments
In a new commentary for the journal
Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective off-the-shelf cancer treatments for more patients.
Jon Weidanz, who also is a professor in the College of Nursing and Health Innovation at UTA, is the author of a perspective regarding the development of cancer immunotherapies.
His article, Targeting cancer with bispecific antibodies, will appear in the March 5 edition of
Science. It evaluates the findings of three studies by researchers at Johns Hopkins University and proposes that an emerging method of protein-based immunotherapy that targets commonly occurring mutations in cancer cells or neoantigens mutated antigens produced by tumor cells could lead to treatments that are effective for oncology patients.
Antibodies Deplete Cancer Cells in Mice and Human Cell Lines by Angela Mohan on March 2, 2021 at 12:14 PM
Science,
Science Immunology.
Some immunotherapy approaches against cancers rely on common cancer-related mutations to serve as antigens; they instigate an immune response to the cancer.
Although it is one of the most common mutant tumor suppressor genes known in human cancers, the cancer-related p53 tumor suppressor gene has not been successfully targeted via this approach.
In
Science, Emily Han-Chung Hsiue and colleagues successfully engineered a bispecific antibody to reactivate p53. Hsiue et al. first identified a distinct targetable fragment of the mutant tumor suppressor protein and characterized the structural basis for how the fragment is presented to T cells.
Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases.
Date Time
Future of immunotherapy could be ‘off-the-shelf’ treatments
In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective “off-the-shelf” cancer treatments for more patients.
Jon Weidanz, who also is a professor in the College of Nursing and Health Innovation at UTA, is the author of a perspective regarding the development of cancer immunotherapies.
His article, “Targeting cancer with bispecific antibodies,” will appear in the March 5 edition of Science. It evaluates the findings of three studies by researchers at Johns Hopkins University and proposes that an emerging method of protein-based immunotherapy that targets commonly occurring mutations in cancer cells or neoantigens mutated antigens produced by tumor cells could lead to treatments that are effective for oncology patients.
New immunotherapy drugs target two evasive cancer-driving proteins sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.